GP v Beacon Pharmaceuticals: unsolicited promotional email for Episenta (breach of Clause 9.9)

📊

Key facts

⌄

Case	AUTH/2022/7/07
Complainant	General practitioner
Company	Beacon Pharmaceuticals Ltd
Product	Episenta (prolonged release sodium valproate)
Issue	Unsolicited promotional email; unsubscribe concerns; reliance on third-party database “opt-in”
Applicable Code year	2006
Clause(s) breached	Clause 9.9
Complaint received	17 July 2007
Case completed	27 September 2007
Appeal	No appeal
Sanction	Undertaking received
Source	https://www.pmcpa.org.uk/cases/completed-cases/auth2022707-gp-v-beacon-pharmaceuticals

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

A general practitioner complained about receiving repeated unsolicited “spam” emails, including an email relating to Episenta (prolonged release sodium valproate) sent on Beacon’s behalf.
The GP said they would not have provided their email address/consent and that the unsubscribe function did not work.
Beacon said it commissioned an agency to produce an “educational email” and distribute it to healthcare workers on the agency’s database, which the agency described as “opt-in”.
The email content was considered promotional: it referenced prolonged release sodium valproate and Episenta, included Beacon branding, and linked to prescribing information.
The agency’s consent approach relied on historic questionnaires and ongoing validation/telephone scripts; the Panel did not have the original questionnaire and found the wording did not clearly obtain consent for pharma promotional emails.
The Panel also noted confusion around opt-out: the agency indicated opt-out had been limited by category/topic unless a “blanket opt-out” was specifically requested.

⚖️

⌄

The Panel ruled the email was unsolicited promotional material.
There was no evidence the complainant had given prior permission to receive promotional emails from a pharmaceutical company.
Breach of Clause 9.9 was ruled.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access